Immunohistochemical Characterisation of the Immune Landscape in Primary Uveal Melanoma and Liver Metastases

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Jul 13

PMID 37443346

Authors

Pascale Mariani

Nouritza Torossian

Steven Van Laere

Peter Vermeulen

Leanne De Koning

Sergio Roman-Roman

Olivier Lantz

Manuel Rodrigues

Marc-Henri Stern

Sophie Gardrat

Laetitia Lesage

Gabriel Champenois

Andre Nicolas

Alexandre Matet

Nathalie Cassoux

Vincent Servois

Emanuela Romano

Sophie Piperno-Neumann

Claire Lugassy

Raymond Barnhill

Affiliations

Soon will be listed here.

Abstract

Background: The immune landscape of uveal melanoma liver metastases (UMLM) has not been sufficiently studied.

Methods: Immune cell infiltrates (ICIs), PD-1 and PD-L1 were characterised in 62 UMLM and 28 primary uveal melanomas (PUM). ICI, PD-1 and PD-L1 were scored as: (1) % tumoral area occupied by tumour-infiltrating lymphocytes or macrophages (TILs, TIMs) and (2) % perTumoral (perT) area. ICIs and other variables including histopathologic growth patterns (HGPs), replacement and desmoplastic, of UMLM were analysed for their prognostic value.

Results: ICIs recognised by haematoxylin-eosin-saffron (HES) and IHC (e.g., T cells (CD3), B cells (CD20). Macrophages (CD68), (CD163), were primarily localised to the perT region in PUM and UMLM and were more conspicuous in UMLM. HES, CD3, CD4, FoxP3, CD8, CD20, PD-1 TILs were scant (<5%). TIMs were more frequent, particularly in UMLM than in PUM. Both CD68+ TIMs and HGPs remained significant on multivariate analysis, influencing overall (OS) and metastasis-specific overall survival (MSOS). CD68 + , CD163+ and CD20+ perT infiltrates in UMLM predicted increased OS and MSOS on univariate analysis.

Conclusions: TILs and PD-L1 have no predictive value in PUM or UMLM. CD68+ and CD163+TIMs, CD20+ perT lymphocytes, and HGPs are important prognostic factors in UMLMs.

Citing Articles

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.

Guc E, Treveil A, Leach E, Broomfield A, Camera A, Clubley J Nat Commun. 2025; 16(1):2374.

PMID: 40064880 PMC: 11893752. DOI: 10.1038/s41467-025-57470-w.

A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma.

Alam B, Akbari A, Ageed A, Duffy R J Clin Med. 2025; 14(3).

PMID: 39941557 PMC: 11818147. DOI: 10.3390/jcm14030885.

Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease.

Bol K, Sweep M, Crowther M, Gorris M, Aroca Lara P, Draghi A Invest Ophthalmol Vis Sci. 2025; 66(2):24.

PMID: 39918475 PMC: 11809448. DOI: 10.1167/iovs.66.2.24.

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

Beigi Y, Lanjanian H, Fayazi R, Salimi M, Hoseyni B, Noroozizadeh M Mol Biomed. 2024; 5(1):17.

PMID: 38724687 PMC: 11082128. DOI: 10.1186/s43556-024-00182-2.

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.

Leonard-Murali S, Bhaskarla C, Yadav G, Maurya S, Galiveti C, Tobin J Nat Commun. 2024; 15(1):2863.

PMID: 38627362 PMC: 11021475. DOI: 10.1038/s41467-024-46906-4.

References

Lee M, Heo S, Song I, Rajayi H, Park H, Park I . Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod Pathol. 2018; 32(1):70-80. DOI: 10.1038/s41379-018-0113-8. View

Zabor E, Radivoyevitch T, Singh A, Kilic E, de Klein J, Kalirai H . Conditional Survival in Uveal Melanoma. Ophthalmol Retina. 2020; 5(6):536-542. DOI: 10.1016/j.oret.2020.09.015. View

Robertson A, Shih J, Yau C, Gibb E, Oba J, Mungall K . Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017; 32(2):204-220.e15. PMC: 5619925. DOI: 10.1016/j.ccell.2017.07.003. View

Orloff M . Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy. Ocul Oncol Pathol. 2021; 7(3):168-176. PMC: 8280448. DOI: 10.1159/000513336. View

Qin Y, Macedo M, Reuben A, Forget M, Haymaker C, Bernatchez C . Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology. 2017; 6(6):e1321187. PMC: 5486182. DOI: 10.1080/2162402X.2017.1321187. View

Lagouros E, Salomao D, Thorland E, Hodge D, Vile R, Pulido J . Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc. 2010; 107:223-8. PMC: 2814577. View

Bronkhorst I, Ly L, Jordanova E, Vrolijk J, Versluis M, Luyten G . Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2010; 52(2):643-50. DOI: 10.1167/iovs.10-5979. View

Radivoyevitch T, Zabor E, Singh A . Uveal melanoma: Long-term survival. PLoS One. 2021; 16(5):e0250939. PMC: 8130945. DOI: 10.1371/journal.pone.0250939. View

Bronkhorst I, Jager M . Inflammation in uveal melanoma. Eye (Lond). 2012; 27(2):217-23. PMC: 3574253. DOI: 10.1038/eye.2012.253. View

10.

Whelchel J, Farah S, McLean I, Burnier M . Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993; 34(8):2603-6. View

11.

Bronkhorst I, Vu T, Jordanova E, Luyten G, van der Burg S, Jager M . Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53(9):5370-8. DOI: 10.1167/iovs.11-9280. View

12.

Gao J, Liang Y, Wang L . Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022; 13:888713. PMC: 9280632. DOI: 10.3389/fimmu.2022.888713. View

13.

Lang J . Lost to follow-up. Arch Ophthalmol. 1977; 95(6):1082. DOI: 10.1001/archopht.1977.04450060169025. View

14.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

15.

Zhou H, Gan M, Jin X, Dai M, Wang Y, Lei Y . miR‑382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumor‑associated macrophages by targeting PGC‑1α. Int J Oncol. 2022; 61(4). PMC: 9477106. DOI: 10.3892/ijo.2022.5416. View

16.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D . Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008; 5(6):e120. PMC: 2408611. DOI: 10.1371/journal.pmed.0050120. View

17.

Makitie T, Summanen P, Tarkkanen A, Kivela T . Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42(7):1414-21. View

18.

Tosi A, Cappellesso R, Dei Tos A, Rossi V, Aliberti C, Pigozzo J . The immune cell landscape of metastatic uveal melanoma correlates with overall survival. J Exp Clin Cancer Res. 2021; 40(1):154. PMC: 8097926. DOI: 10.1186/s13046-021-01947-1. View

19.

Van Dam P, van der Stok E, Teuwen L, Van den Eynden G, Illemann M, Frentzas S . International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer. 2017; 117(10):1427-1441. PMC: 5680474. DOI: 10.1038/bjc.2017.334. View

20.

Ricketts T, Prieto-Dominguez N, Gowda P, Ubil E . Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Front Immunol. 2021; 12:642285. PMC: 8139576. DOI: 10.3389/fimmu.2021.642285. View